NCT05510908 · STUDY IN CONTEXT

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

exploratory · POSTED

The distribution of participant cancer diagnosis variable will be summarized.

Participants who enrolled in this study

→

exploratory · POSTED

The distribution of participant gender variable will be summarized.

Participants who enrolled in this study

→

exploratory · POSTED

The distribution of participant characteristics will be summarized. Continuous variables \[e.g. age, height, weight\] will be summarized as mean (std) if they are normally distributed, otherwise they will be summarized as median (IQR). Categorical variables \[e.g. tobacco use, ART medications, comorbidities\] will be summarized as frequency (%).

Participants who enrolled in this study

→

exploratory · POSTED

The distribution of participant cancer treatment at enrollment will be summarized.

Participants who enrolled in this study

→

primary · POSTED

For each cancer group listed below, the number of new and existing cases per month will be estimated. The distribution of cancer types will be computed as percentages and compared to the cancer type distribution in the HIV/AIDS Cancer Match (HACM) Study: 1. Solid organ tumors associated with human papillomavirus (HPV) infection 2. Solid organ tumors unrelated to HPV 3. Kaposi sarcoma 4. Hematologic malignancies

Source null

→

secondary · POSTED

This will be calculated by the number of participants enrolled who meet site-based AMC trial eligibility compared to the number of eligible participants at each site who meet site-based AMC trial eligibility.

The participants who are eligible to meet site-based AMC trial eligibility

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

EORTC QLQ · Describe the Health-related QOL of Cancer Patients With HIV at Domestic AMC Sites Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id: clinical-indications-draft-1
disease state id: ds-anal-cancer
nct id: NCT05510908
qol key: qol-0007
source section id: NCT05510908-om-0007
source outcome index: 7
instrument: EORTC QLQ
instrument basis: matched 'eortc' in the study's own wording
scale title: Describe the Health-related QOL of Cancer Patients With HIV at Domestic AMC Sites Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
measure definition: EORTC QLQ-C30 subscale and overall scores will be used to describe participant symptom and health-related quality of life burden. Baseline EORTC QLQ-C30 scores will be compared according to cancer group. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and single items assessing additional symptoms and perceived financial impact of the disease. Most questions use a 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions use a 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.
time frame: Baseline
analysis role: exploratory
reporting status: POSTED
higher is better: Source null
direction quote: Source null
population note: Participants who enrolled in this study with EORTC QLQ-C30 information
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Open the exact result →

EORTC QLQ · Change of Quality of Life at 12 Weeks From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id: clinical-indications-draft-1
disease state id: ds-anal-cancer
nct id: NCT05510908
qol key: qol-0009
source section id: NCT05510908-om-0009
source outcome index: 9
instrument: EORTC QLQ
instrument basis: matched 'eortc' in the study's own wording
scale title: Change of Quality of Life at 12 Weeks From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
measure definition: EORTC QLQ-C30 will be summarized, both overall and at the \~12-week follow-up, according to participant characteristics and cancer groups. Overall change in QOL will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role,cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms and perceived financial impact of the disease. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.
time frame: Baseline and 12 weeks
analysis role: exploratory
reporting status: POSTED
higher is better: Source null
direction quote: Source null
population note: Participants who enrolled with EORTC QLQ-C30 measurements for baseline and 12 weeks
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Open the exact result →

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-anal-cancer
nct id: NCT05510908
trial label: Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 6
harms Count: 3
qol Count: 2

outcomes

release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0002
source section id
NCT05510908-om-0002
source outcome index
2
endpoint
Describe the Cancer Diagnostics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
endpoint definition
The distribution of participant cancer diagnosis variable will be summarized.
time origin
Baseline
analysis role
exploratory
reporting status
POSTED
data cutoff
Source null
population note
Participants who enrolled in this study
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0003
source section id
NCT05510908-om-0003
source outcome index
3
endpoint
Describe the Gender Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
endpoint definition
The distribution of participant gender variable will be summarized.
time origin
Baseline
analysis role
exploratory
reporting status
POSTED
data cutoff
Source null
population note
Participants who enrolled in this study
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0004
source section id
NCT05510908-om-0004
source outcome index
4
endpoint
Describe the Age Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
endpoint definition
The distribution of participant characteristics will be summarized. Continuous variables \[e.g. age, height, weight\] will be summarized as mean (std) if they are normally distributed, otherwise they will be summarized as median (IQR). Categorical variables \[e.g. tobacco use, ART medications, comorbidities\] will be summarized as frequency (%).
time origin
Baseline and 12 weeks
analysis role
exploratory
reporting status
POSTED
data cutoff
Source null
population note
Participants who enrolled in this study
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0005
source section id
NCT05510908-om-0005
source outcome index
5
endpoint
Describe the Treatment Characteristics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
endpoint definition
The distribution of participant cancer treatment at enrollment will be summarized.
time origin
Baseline
analysis role
exploratory
reporting status
POSTED
data cutoff
Source null
population note
Participants who enrolled in this study
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0000
source section id
NCT05510908-om-0000
source outcome index
0
endpoint
Number of Cancers in People With HIV (PWH) Who Present for Care at Domestic AMC Sites
endpoint definition
For each cancer group listed below, the number of new and existing cases per month will be estimated. The distribution of cancer types will be computed as percentages and compared to the cancer type distribution in the HIV/AIDS Cancer Match (HACM) Study: 1. Solid organ tumors associated with human papillomavirus (HPV) infection 2. Solid organ tumors unrelated to HPV 3. Kaposi sarcoma 4. Hematologic malignancies
time origin
Enrollment
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0001
source section id
NCT05510908-om-0001
source outcome index
1
endpoint
Proportion of Participants Eligible for AMC Trials Who Are Successfully Enrolled
endpoint definition
This will be calculated by the number of participants enrolled who meet site-based AMC trial eligibility compared to the number of eligible participants at each site who meet site-based AMC trial eligibility.
time origin
Baseline
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
The participants who are eligible to meet site-based AMC trial eligibility
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0000
arm key
OG000
arm label
New, Primary or Recurrent Disease
regimen
Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
analyzed count
268
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05510908-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0000
arm key
OG001
arm label
Metastic or Locally Advanced Cancer
regimen
This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
analyzed count
33
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05510908-om-0000#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0000
arm key
OG002
arm label
Prior Cancer
regimen
Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
analyzed count
159
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05510908-om-0000#groups/OG002
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0001
arm key
OG000
arm label
New, Primary or Recurrent Disease
regimen
Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
analyzed count
20
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05510908-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0001
arm key
OG001
arm label
Metastic or Locally Advanced Cancer
regimen
This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
analyzed count
2
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05510908-om-0001#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0001
arm key
OG002
arm label
Prior Cancer
regimen
Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
analyzed count
4
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05510908-om-0001#groups/OG002
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0002
arm key
OG000
arm label
New, Primary or Recurrent Disease
regimen
Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
analyzed count
268
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05510908-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0002
arm key
OG001
arm label
Metastic or Locally Advanced Cancer
regimen
This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
analyzed count
33
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05510908-om-0002#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0002
arm key
OG002
arm label
Prior Cancer
regimen
Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
analyzed count
159
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05510908-om-0002#groups/OG002
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0003
arm key
OG000
arm label
New, Primary or Recurrent Disease
regimen
Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
analyzed count
268
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05510908-om-0003#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0003
arm key
OG001
arm label
Metastic or Locally Advanced Cancer
regimen
This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
analyzed count
33
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05510908-om-0003#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
outcome key
om-0003
arm key
OG002
arm label
Prior Cancer
regimen
Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
analyzed count
159
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05510908-om-0003#groups/OG002

harms

release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
harm key
EG000
source section id
NCT05510908-ae
event group key
EG000
event group label
New, Primary or Recurrent Disease
serious affected
0
serious at risk
0
other affected
0
other at risk
0
frequency threshold
0
collection period
This study is observational study. Adverse events are not collected.
event definition
This study is observational study. Adverse events are not collected.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
harm key
EG001
source section id
NCT05510908-ae
event group key
EG001
event group label
Metastic or Locally Advanced Cancer
serious affected
0
serious at risk
0
other affected
0
other at risk
0
frequency threshold
0
collection period
This study is observational study. Adverse events are not collected.
event definition
This study is observational study. Adverse events are not collected.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
harm key
EG002
source section id
NCT05510908-ae
event group key
EG002
event group label
Prior Cancer
serious affected
0
serious at risk
0
other affected
0
other at risk
0
frequency threshold
0
collection period
This study is observational study. Adverse events are not collected.
event definition
This study is observational study. Adverse events are not collected.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
qol key
qol-0007
source section id
NCT05510908-om-0007
source outcome index
7
instrument
EORTC QLQ
instrument basis
matched 'eortc' in the study's own wording
scale title
Describe the Health-related QOL of Cancer Patients With HIV at Domestic AMC Sites Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
measure definition
EORTC QLQ-C30 subscale and overall scores will be used to describe participant symptom and health-related quality of life burden. Baseline EORTC QLQ-C30 scores will be compared according to cancer group. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and single items assessing additional symptoms and perceived financial impact of the disease. Most questions use a 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions use a 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.
time frame
Baseline
analysis role
exploratory
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Participants who enrolled in this study with EORTC QLQ-C30 information
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT05510908
qol key
qol-0009
source section id
NCT05510908-om-0009
source outcome index
9
instrument
EORTC QLQ
instrument basis
matched 'eortc' in the study's own wording
scale title
Change of Quality of Life at 12 Weeks From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
measure definition
EORTC QLQ-C30 will be summarized, both overall and at the \~12-week follow-up, according to participant characteristics and cancer groups. Overall change in QOL will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role,cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms and perceived financial impact of the disease. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.
time frame
Baseline and 12 weeks
analysis role
exploratory
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Participants who enrolled with EORTC QLQ-C30 measurements for baseline and 12 weeks
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

setting source links

Preserved source evidence · Not medical advice